Categories Earnings, Health Care
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, on Monday reported an increase in revenue and adjusted profit for the first quarter of 2025.
- Revvity reported revenue of $665 million for the March quarter, compared to $650 million in the same period a year ago
- In the Life Sciences segment, revenue and organic revenue increased 1% and 2%, respectively, during the three months
- Diagnostic revenue moved up 3% YoY in Q1, Diagnostic organic revenue increased by 5%
- Reported earnings, on a per-share basis, increased to $0.35 in the first quarter from $0.21 in the prior-year period
- Adjusted earnings from continuing operations were $1.01 per share in Q1, vs. $0.98 per share in the first quarter of 2024
- Operating profit margin from continuing operations was 10.9% as a percentage of revenue, compared to 6.8% in the year-ago quarter
- The company raised its full-year revenue guidance to a range of $2.83-$2.87 billion, reflecting recent changes in foreign currency exchange rates
- It reaffirmed its adjusted earnings per share guidance in the range of $4.90 and $5.00
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
